Evidence map›Paper›PMID 36979456›Full record

ArticleBiomolecules2023

Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation.

Xia Xu, Xuejiao Tian, Liankun Song, Jun Xie, Joseph C Liao, Joshua J Meeks, Xue-Ru Wu, Greg E Gin, Beverly Wang, Edward Uchio and 1 more

Open access · goldFull text read
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Opportunities and Challenges of Kava in Lung Cancer Prevention.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Xia XuDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Xuejiao TianDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.ORCID 0000-0002-8044-0684
Liankun SongDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Jun XieDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Joseph C LiaoVeterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, USA.
Joshua J MeeksJesse Brown VA Medical Center, 820 S Damen Ave, Chicago, IL 60612, USA.
Xue-Ru WuVeterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA.
Greg E GinDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Beverly WangDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA 92868, USA.
Edward UchioDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Xiaolin ZiDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
University of California, Irvine · USJesse Brown VA Medical Center · USVA NY Harbor Healthcare System · USVA Palo Alto Health Care System · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Reagent/Service CoreP01CA165980 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, XUE-RU · 2013 to 2023
$13.5M
Urothelial Stem CellsR01DK110466 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, XUE-RU · 2017 to 2020
$2.6M
The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKAR01CA193967 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2016 to 2020
$1.8M
Chemoprevention of urinary bladder carcinogenesis by flavokawain AR01CA122558 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2008 to 2012
$1.7M
BLR&D Research Career Scientist Award ApplicationIK6BX004479 · VA · VA MEDICAL CENTER · PI WU, XUE-RU · 2019 to 2025
–
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Role of PPARg in theFormation and Progression of Carcinoma in situ of the BladderI01BX005602 · VA · VA MEDICAL CENTER · PI XUE-RU WU · 2022 to 2026
–
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Leveraging Artificial Neural Networks to Enhance Detection of Carcinoma in situI01BX005598 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI JOSEPH C LIAO · 2022 to 2026
–
CMA-Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Interception of tobacco smoking-related bladder cancer by an epigenetic approachI01BX005597 · VA · VETERANS HEALTH ADMINISTRATION · PI ZI, XIAOLIN · 2022 to 2025
–
BLRD VA I01 BX003692BLRD VA I01 BX005597BLRD VA I01 BX005598BLRD VA I01 BX005599BLRD VA I01 BX005602BLRD VA IK6 BX004479NCI NIH HHS P01 CA165980NCI NIH HHS P30 CA062203NCI NIH HHS R01CA122558NCI NIH HHS R01 CA193967NIDDK NIH HHS R01 DK110466
6 · The paper itself

Abstract

Epidemiological evidence suggests that kava (

Indexed as

Urinary BladderUrinary Bladder NeoplasmsAnimalsCarcinogenesisEpigenesis, GeneticHistone DemethylasesHumansLysineMicePyronesUp-RegulationHistone DemethylaseskavainLysinePyronesbladder cancerchemopreventionkavaLSD1

Identifiers

PMID36979456
PMCPMC10046577
OpenAlexW4324055992

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read45
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.